Brain tumors, Spinal cord tumors, Metastatic brain tumors, Alternating electric field therapy, Genome-guided therapy, Stem cell-based therapies, Neuro-immunotherapies, Enhanced imaging techniques, Early phase clinical trial design
Fellowship, Neurological Oncology, Duke University Hospital, 2015 – 2016; Fellowship, Hematology and Medical Oncology, Tufts Medical Center, 2012 – 2015; Residency, Internal Medicine, Dartmouth-Hitchcock Medical Center, 2010 – 2012; Internship, Internal Medicine, Dartmouth-Hitchcock Medical Center, 2009 – 2010; M.D. and B.A.,University of Missouri, Kansas City in an accelerated combined program, 2002 – 2009
Research and Clinical Interests
As the director of the UNC Brain Tumor Program, Dr. Khagi works in close collaboration with a wide range of supportive specialties to provide patients with a truly multidisciplinary approach to the treatment of central nervous system malignancies.
In addition to his extensive experience with chemotherapy and genomic-guided therapy, he is also certified in the application of alternating electric field therapy (i.e., Optune) for the treatment of glioblastoma. His research efforts center around improving treatments for patients with aggressive brain tumors (i.e., glioblastoma) and metastatic disease to the brain from lung cancer. Specifically, his research focuses on novel stem cell-based therapies, neuro-immunotherapeutics, design of early phase clinical trials, and enhanced imaging techniques for brain tumors.